Global Journal of Machine Learning and Computing

ISSN : 3079-692X
Volume 1, Number 2, 2025
https://doi.org/10.70445/gjmlc.1.2.2025.93-111

Quality by Intelligence: A Review of AI Applications in Healthcare Product Lifecycle Management

Muhammad Mohsin Kabeer[1*]

[1, 2] Project Management Institution (PMI), United States of America, American Purchasing Society (APS) United States of America

[1]Mohsinkabeer86@gmail.com

Corresponding Author

Muhammad Mohsin Kabeer
Mohsinkabeer86@gmail.com

Article History:

Submitted: 24-10-2025

Accepted: 25-11-2025

Published: 30-11-2025

Keywords

Artificial Intelligence, Healthcare, Product Development, Quality Assurance, Regulatory Compliance, Digital Twins.

ABSTRACT

The evolution of healthcare products development and their quality assurance is changing rapidly owing to the artificial intelligence (AI), as it allows quicker innovation, increased safety, and better regulatory compliance. The paper discusses the role of AI technologies in the whole product lifecycle, starting with early research and design and continuing with prototyping, manufacturing, and after-sale surveillance. The main advantages are automated defect detection, predictive analytics, optimization of processes, and intelligent decision support that, respectively, enhance the quality of products and patient safety. Other regulatory considerations, ethical issues, and restrictions discussed in the review include data quality and model transparency. Lastly, there are new adaptive AI, digital twins, and patient-centric trends, which represent the future path of AI-driven healthcare innovation.

INTRODUCTION

One of the most significant technological powers that have changed the current healthcare environment is artificial intelligence (AI). As healthcare systems become more data-driven and automated, with the use of intelligent decision-support tools and automation, AI is increasingly being incorporated into the core of medical device and pharmaceutical innovation, diagnostics, and digital

ISSN : 3079-692X
Volume 1, Number 2, 2025
https://doi.org/10.70445/gjmlc.1.2.2025.93-111

health innovations [1]. The opportunity to analyze large volumes of data, learn the patterns, and make predictions can open up new opportunities that have never been available in terms of enhancing the efficiency of the healthcare product development as well as its results [2].

Development of healthcare products is a long, complicated, and highly controlled process with several stages that comprise research, design, prototyping, testing, validation, regulatory review, and post-market surveillance. Quality, safety and compliance are the most important at every stage. Nevertheless, traditional methods can be easily trapped by the following problems: time-consuming development cycles, human factor, low data integration and expensive nature. The AI-based innovation can mitigate these restrictions by making the design process smarter, predictive, quality checks automated, and decision-making more advanced [3].

When applied in the early stages of development, AI helps to conduct ideation and unmet clinical needs faster by examining clinical data, patient record, scientific literature, and real-world evidence. The models of machine learning can demonstrate trends, which can be used to create concepts and assist developers in prioritizing the features of products according to the real needs of the population. In design and prototyping, AI-based simulations and digital twins can be used to forecast the performance of the product as well as its optimization and minimize trial and error commonly involved in the case of physical prototyping [4]. AI integration can also be of great help in quality assurance (QA) and quality control (QC). The AI-driven systems can be used to automate defects, conduct ongoing monitoring, forecast failures, and offer real-time analytics to ensure that the products are of high quality and comply with strict requirements of healthcare. These capabilities not only enhance accuracy and reliability of the quality checks but also lower the cost of operation and increase traceability; aspects that are very important in the compliance with regulations [5].

The regulatory organizations, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) are paying more attention to the potential of AI as a transformative technology and insisting on transparency, explain ability, and validation of algorithms employed in healthcare products. With developers expanding AI usage across the product lifecycle, regulatory issues also become more imperative and must have robust structures to show how models can be reliable, risk controlled and safe to patients [6]. In general, AI-based innovation is a paradigm shift of the development of healthcare products. Through quality improvements, faster development cycles, and aiding stricter compliance, artificial intelligence will transform the concept of safe and effective healthcare products and engineering and delivering those [7].

Global Journal of Machine Learning and Computing

ISSN : 3079-692X
Volume 1, Number 2, 2025
https://doi.org/10.70445/gjmlc.1.2.2025.93-111

OVERVIEW OF AI TECHNOLOGIES RELEVANT TO HEALTHCARE PRODUCT DEVELOPMENT

AI is a wide range of technologies that include the impactful technologies in healthcare products development and quality assurance. These technologies are more complex, functional, and capable of application, but they all lead to achieving greater innovation acceleration, enhanced accuracy, and enhanced regulatory preparedness throughout the product lifecycle [8]. Machine learning (ML) has been one of the most fundamental fields of AI and allows systems to learn on the basis of data and also to learn as time goes by without being programmed to handle all situations. ML algorithms in the development of healthcare products aid in predicting performance of the devices, optimizing manufacturing process, predicting product failure, and detecting the potential safety issue at the early stages of product design. Supervised learning techniques are used to classify defects or to gauge product behavior whereas unsupervised learning may be used to reveal concealed patterns of clinical data or operational data [9].



Figure: 1 showing AI technologies relevant to healthcare

The Deep learning (DL), a subfield of ML, is applied to analyze multi-layered artificial neural networks to analyze large datasets like medical images, sensor data, and data on usage in the real world. DL models are also used to improve the development of a product as they allow advanced functionality, like automated image-based detection of defects, enhancement of diagnostic equipment

ISSN : 3079-692X
Volume 1, Number 2, 2025
https://doi.org/10.70445/gjmlc.1.2.2025.93-111

accuracy, and the use of simulation to test the product. The capability to process high-dimensional and unstructured data produced by deep learning can prove especially useful in creating advanced devices of imaging, wearable, and smart diagnostic tools [10]. NLP is used to extract valuable information about unstructured data in the form of clinical notes, regulatory documents, scientific literature and customer feedbacks. NLP is useful in product development whereby it assists in literature reviews, risk identification, design inputs, and automated documentation processes. NLP also simplifies manual workload and limits the number of human errors in important documentation by automating the process of interpreting huge text-based datasets [11].

The other disruptive domain is computer vision which enables the AI systems to process visual information. In the manufacturing and QA industry, computer vision is used in detecting defects in real-time, inspecting surfaces, verifying measurements and checking assembly lines. These features enhance quality control much better and also less variability [12]. Decision-making is further promoted by predictive analytics and generative AI. Predictive analytics assists in predicting the product performance patterns, maintenance requirements and the possible risks in advance so that the quality can be promoted. In the meantime, generative AI helps in optimization of designs, documentation writing, and modeling simulations [13]. Combined, these AI technologies create a massive ecosystem that improves all stages of healthcare product development, and it includes conceptualization and prototyping, manufacturing, testing, and quality assurance, which, in the end, is meant to enable safer, more reliable, and efficient healthcare developments [14].

AI APPLICATIONS ACROSS THE HEALTHCARE PRODUCT DEVELOPMENT LIFECYCLE

The change in the lifecycle of healthcare products development is brought by artificial intelligence that implements new capabilities based on data to facilitate smarter decision-making, shorter development cycles, and improved product quality. Since the initial phases of research to the ultimate implementation, AI tools are becoming a part of work processes to improve processes, reduce risks, and guarantee safe and effective healthcare technologies [15]. Early-stage research and ideation AI is extremely important because it helps analyze clinical data, scientific literature, real-world evidence, and patient demographics significantly. Natural language processing and machine learning are used to detect unexpressed medical needs, the new disease trends, and therapeutic opportunities. These lessons can inform developers to develop products with real clinical value and solve actual clinical gaps. It goes so far as AI tools can forecast possible adoption pattern of the market and can assist the company to focus on high impact innovations [16].

Global Journal of Machine Learning and Computing
ISSN : 3079-692X
Volume 1, Number 2, 2025
https://doi.org/10.70445/gjmlc.1.2.2025.93-111



Figure: 2 showing healthcare product development

At design and prototyping, computer simulated models and computer twins are speeded up by AI. These computer-based models of products enable the developers to experiment on different design options, model the product behavior in different conditions and even determine possible defects prior to developing real prototypes. This saves money, cuts the trial and error lifecycle, and provides chances to have more specific and tailor-made product designs, particularly in the field of prosthetics, implants, and system of diagnostic imaging [17]. Another aspect of AI development is that AI supports development and optimization stages by automating routine processes, making it possible to conduct predictive analytics and monitor processes more effectively. In computerized medical equipment or digital health programs, artificial intelligence can be used to help improve performance over time as it uses the usage information and identifies opportunities to improve the software [18]. Machine learning models are used in manufacturing settings to optimize the production parameters, predict the bottlenecks, and identify the initial signs of equipment malfunction. These features make the product performance and production workflow consistent.

In the process of testing and validation, AI-based tools are valuable to support sound data analysis,

ISSN : 3079-692X
Volume 1, Number 2, 2025
https://doi.org/10.70445/gjmlc.1.2.2025.93-111

automated performance reviews, and risk assessments. Deep learning models would be able to work with huge testing data and determine the presence of minor anomalies or deviations, which can be not detected with a conventional testing method [19]. Moreover, virtual clinical trials are achieved with the help of AI-based simulation platforms and allow cutting expenses on long and expensive physical trials, primarily in the early stages of testing. The implementation of AI throughout the healthcare product development lifecycle results into accelerated innovation, more precise designs, cost reduction, and a better fit with established regulatory requirements. Using AI as a strategic tool, the developers can introduce safer and more useful healthcare solutions to the market more effectively than ever [20].

AI IN QUALITY ASSURANCE AND QUALITY CONTROL

Quality assurance (QA) and quality control (QC) are indispensable elements of the healthcare product development since they are used to ensure that medical devices, pharmaceuticals, diagnostics, and digital health solutions meet high standards of safety, performance, and regulatory standards. Through automation of inspections, increased accuracy, minimization of errors in humans, and continuous monitoring of the process, artificial intelligence has turned into a transformational force in QA/QC [21]. With AI-based technologies, organizations will be able to reach greater reliability, reduce operational expenses and decrease the time of releasing new products yet still adhere to the strict compliance criteria [22].

Automated testing and defect detection is one of the greatest AI uses in QA/QC. Deep learning algorithms can generate computer vision systems that can check goods with a very high level of accuracy, even identifying minor flaws that are not always noticed by human operators. Such systems assess the surface defects, structural defects, calibration problems and assembly defects on run time. Through constant learning of new information, the AI models can be enhanced to classify defects over time, and this will lead to more quality checks and fewer false positives or negatives [23]. Another important way AI can be used is to allow predictive maintenance and anomaly detection in the manufacturing world. Machine learning algorithms process equipment performance information to predict the need to conduct maintenance before failure of equipment. This proactive method ensures that there is minimal time lost due to timing, the likelihood of having defective batches of products, and the general stability of the processes. Early warning of temperature, pressure or vibration anomalies can be used to ensure that manufacturing conditions are observed within known and validated ranges which can be directly linked to regulatory compliance [24].

Global Journal of Machine Learning and Computing
ISSN : 3079-692X
Volume 1, Number 2, 2025
https://doi.org/10.70445/gjmlc.1.2.2025.93-111



Figure: 3 showing AI in quality assurance

AI has been associated with risk management in the setting of Quality-by-Design (QbD), where it is able to identify the most important quality attributes and process parameters. Data-driven models are those that predict the impact of changes in materials, environment, or processes to be used in the production process on the end product [25]. These lessons assist businesses to maximize operations and minimize variability as well as produce products that continue to perform as per the specifications. Such a strategy is consistent with the modern regulatory requirements of sound, science-grounded quality management [26].

Automated documentation and change management is another AI application that can be used to transform QA/QC. Tools that are based on natural language processing have an ability to extract, categorize, and structure information which is contained in quality records, test reports and regulatory documents. This automation will provide traceability, less manual documentation, and less human error in compliance activities [27]. The version histories, changes, and audit preparedness can also be tracked by AI systems, which offer ordered and searchable digital quality archives. AI improves quality assurance and control by providing speed, accuracy, scalability, and continuous improvement which are the pillars of safe and compliant healthcare products

Global Journal of Machine Learning and Computing
ISSN : 3079-692X
Volume 1, Number 2, 2025
https://doi.org/10.70445/gjmlc.1.2.2025.93-111

REGULATORY CONSIDERATIONS AND COMPLIANCE

Since the evolution of artificial intelligence continues to influence healthcare products, the idea of regulation has taken a more prominent place in the framework of making AI-enabled products safe, effective, and trustworthy. Healthcare is a very regulated industry, and AI implementation brings additional complexities to the areas of transparency, model validation, data management, and the lifecycle. The various regulatory authorities around the world are developing frameworks to deal with the peculiarity of AI-based technologies, especially those that are considered as Software as a Medical device (SaMD) or AI as a Medical device (AIaMD) [29].

One of the fundamental regulatory standards is the ability to prove the safety, accuracy and strength of AI models. In contrast to the conventional software, AI systems are able to learn along with new data and improve over time, which casts doubt on consistency and reliability. Regulators would like developers to deliver clear descriptions of the process of training, validating, and testing algorithms [30]. This involves the description of training experiments, possible bias, model behavior, and the reliability of the AI system when applied in various groups of patients and in real-world scenarios. Good documentation is a major requirement to promote regulatory submissions and audits [31].



Figure: 4 showing principles of AI in healthcare

The validation and verification of AI models is also another key point in which the regulators focus on explain ability, reproducibility, and risk management. To ensure that the output of the model is within the clinical or operational needs, developers should thoroughly test the model using different

ISSN : 3079-692X
Volume 1, Number 2, 2025
https://doi.org/10.70445/gjmlc.1.2.2025.93-111

datasets. Checks are also conducted through stress testing, sensitivity analysis, and test within edge-case scenarios. In the case of models that are automatically updated or self-improving, regulators are shifting to frameworks that need a pre-determined plan of change control in which companies will update their systems on a controlled basis without being re-approved on a case-by-case basis [32].

Ethical and legal issues, including patient privacy, algorithmic fairness, accountability, and cybersecurity are also matters related to regulation. AI models in healthcare are based on massive datasets, and, therefore, it is essential to have privacy regulations, including HIPAA, GDPR, and local data protection regulations [33]. The developers have to ensure high data governance rules to guard patient information. Moreover, equity is another significant regulatory issue; discriminatory algorithms may cause the wrong or dangerous results to particular demographic groups. Regulatory agencies promote proper evaluation of bias and avoidance measures to promote fair product performance [34].

The regulatory bodies emphasize the need of AI-powered products to be monitored in the post-market phase. The operation of persistent monitoring should be implemented to monitor real-world performance, identify the arising risks, and update the models in a responsible way. The developers are supposed to keep comprehensive records, monitor deviations and report safety concerns in a timely manner [35]. Regulatory compliance becomes a pillar of effective AI implementation in healthcare products development to be sure that new technologies do not violate the global safety, quality, and ethical responsibility standards [36].

CASE STUDIES AND REAL-WORLD IMPLEMENTATIONS

The practical application of artificial intelligence in the development of healthcare products provides useful insights on the efficiency, accuracy, and the overall quality of the product as developed using AI-driven solutions. The case studies illustrate the usefulness of AI in the pharmaceutical, medical device, diagnostics, and manufacturing settings. They also show how organizations can deal with regulatory, technical, and operational hurdles and make AI integration into the workflow successful [37].

The application of AI in pharmaceutical discovery and development is one of the most interesting examples. Some of the major pharmaceutical firms have embraced machine learning models to be used in the analysis of molecular structures, drug-target interactions, and the identification of promising therapeutic leads. The application of AI-based solutions in oncology and rare disease research has tremendously shortened the time to research and development early stages [38]. This technology will reduce the loss of money and speed up the process of developing drugs by screening potential compounds before they go through lab testing. In other instances, AI-assisted discovery has

ISSN : 3079-692X
Volume 1, Number 2, 2025
https://doi.org/10.70445/gjmlc.1.2.2025.93-111

reduced the time needed to carry out research in the early stage by up to 50 per cent, which underscores the transformative effect of AI in the context of product innovation [39].

Digital twins and simulation models that are AI-powered in the context of developing medical devices have allowed manufacturers to virtually test the work of devices under a variety of physiological and environmental conditions. In one example, developers of cardiovascular devices simulate AI-assisted blood flow to calculate the dynamics of blood flow and determine the durability of materials and geometries of devices, as well as optimize the geometries to produce real prototypes. It is much less expensive, and the development time is also minimized, and this technique will also improve the safety of the design since any weakness will be noticed earlier in the design [40].

Artificial intelligence has also been extremely successful in quality inspection and production. Computer vision systems on the production lines of the manufacture of medical devices detect defects or flaws on the surface, assembly, or dimensional errors more precise than the traditional inspection handled by humans. In a single implementation, a visual inspection system based on AI decreased the rate of defect escape by over 30 percent, which helps in enhancing product reliability and compliance. Likewise, predictive maintenance devices employed in pharmaceutical manufacturing process access the data on the equipment and predict failures to ensure that they do not cause a downturn and the quality of production remains constant [41].

There is also the successful implementation of AI-enabled diagnostic products development. AI algorithms on imaging devices are used in identifying diseases including diabetic retinopathy, nodules in the lung, and heart conditions. These resources enhance the quality of the diagnosis and assist clinicians, which provide patients with the timely treatment [42]. These case studies help to understand that the implementation of AI results in the acceleration of the development process, increasing the quality of products, decreasing the costs of operations, and increasing the degree of compliance with the regulations- artificial intelligence can be viewed as one of the crucial elements of the innovation in the health care of the modern era [43].

CHALLENGES AND LIMITATIONS

Although artificial intelligence can revolutionize the product development and quality assurance of healthcare products, there are a number of challenges and limitations that still pose a barrier to its smooth implementation. These are both technical, ethical, regulatory, and operational in nature, so organizations need to use strategic solutions to maximize the utility of AI without sacrificing the safety, reliability, and compliance [44]. Accessibility and quality of data is one of the key challenges. The models of AI rely on the significant amounts of quality information, but healthcare data is most likely to be fragmented, inconsistent, and located in systems that are not compatible. Electronic health

ISSN : 3079-692X
Volume 1, Number 2, 2025
https://doi.org/10.70445/gjmlc.1.2.2025.93-111

records, lab systems, imaging archives and product testing databases are often not standardized and thus, difficult to integrate data. Also, the lack of values, the biasness of the datasets, and lack of representation of minorities can undermine the image of the model. A variety of well-rawed and properly annotated datasets are necessary but a major challenge [45].

The second weakness is that many advanced AI models, in particular, deep learning systems, lack transparency and explainability. Regulatory authorities and medical practitioners need a clear explanation of how the AI models make decisions, especially when the decision would affect the safety of patients or the performance of their products. This can lead to a lack of trust in black-box algorithms, difficulty in obtaining regulatory approval, and legal and ethical liability of organizations. One of the priorities is creating explainable tools of AI that can be easily interpreted without compromising complexity [46].

There are also technical constraints such as the difficulty with model generalizability. Artificially intelligent systems that have been trained under controlled conditions can fail when the conditions become real world or when the applied manufacturing changes or when dealing with heterogeneous groups of patients. This poses threats of poor forecasting or diminished product performance especially on safety-related equipment [47]. Another problem that makes AI adoption complicated is operational issues. The problem of skills gaps exists; many organizations do not have staff that would be skilled in data science, AI engineering, regulatory affairs, and the knowledge of the healthcare domain. The implementation of AI into the current processes often involves huge investments in infrastructure, software integration, and change management. These investments may be prohibitive to smaller organizations, especially [48].

Ethical and legal restrictions are also important. Among the issues raised are patient privacy, bias in the algorithms, ownership of data, and responsibility of the decisions made by AI. Regulatory compliance, including the GDPR, HIPAA, and future AI regulatory requirements, demand a well-planned and solid data governance model. There is uncertainty in regulations. Although regulators are aware of the value of AI, the principles of innovation are changing, and there are no harmonized global standards that may slow the pace of innovation and create uncertainty among manufacturers who want to be approved. On the whole, these problems should be considered in order to make sure that the development of AI and its application to healthcare products and quality assurance could be ensured safely, ethically, and effectively [49].

FUTURE DIRECTIONS

AI in healthcare product development and quality assurance has a bright future of transformative growth because of the development of algorithms, increased computational power, and the

ISSN : 3079-692X
Volume 1, Number 2, 2025
https://doi.org/10.70445/gjmlc.1.2.2025.93-111

availability of data. With the growing level of digitization in the healthcare ecosystem, it is likely that AI will soon be more of an auxiliary tool rather than a fundamental part of product innovation, compliance, and lifecycle. There are a number of important trends and new directions which reflect the path to the adoption of AI in this area [50].

A notable direction of the future will be the creation of adaptive and constantly learning AI models. Adaptive models can also change according to new information as opposed to fixed algorithms, and be within the regulatory limits. This will enable the medical products to react dynamically to changing clinical evidence, manufacturing differences and patient population needs. Constant improvement models would optimize the performance of devices, individualized treatment delivery, and might enhance the accuracy of diagnosing over time in order to support safer and more effective healthcare solutions [51].

Another potential prospect is the integration of AI and digital twins, IoT, and robotics. It can become possible using a combination of digital twins, as a virtual representation of a physical device or a biological system, with real-time IoT sensor data to predictive simulations and proactive risk management [52]. The combination of robotics and AI can reduce human error and scale and precision through the automation of repetitive manufacturing and quality assurance. These integrations will produce complete, smart healthcare manufacturing systems that will be able to innovate fast and maintain high quality control [53].

Explainable AI (XAI) and the technologies that can enhance trust are likely to emerge. Patient safety and other aspects of healthcare make regulatory agencies and healthcare stakeholders progressively insist on transparency in AI-based decisions. The future AI systems must be in a position to deliver comprehensible responses, explainable reason courses, and transparent validation history, which must guarantee clinician confidence and regulatory acceptance. Responsible development will be also steered by ethical frameworks of AI, which will focus on fairness, privacy, and accountability [54].

The growth of the AI-based regulatory support is also expected. AI will help with submission preparation, analysis of regulatory papers, as well as predict compliance results and make approvals less time-consuming and less complex. AI-based post-market surveillance systems will provide an improvement in real-world safety monitoring of devices, proactive detection of adverse events, and further improvement of products [55]. The intersecting of AI and personalized medicine and patient-centric design will transform the development of healthcare products. AI can facilitate extremely personalized treatment, adaptive technologies, and precision diagnostics by using genomic information, patient-reported outcomes, and real-life evidence that will ultimately enhance clinical outcomes and satisfaction among patients [56].

Global Journal of Machine Learning and Computing
ISSN : 3079-692X
Volume 1, Number 2, 2025
https://doi.org/10.70445/gjmlc.1.2.2025.93-111

To summarize, AI is a paradigm shift of healthcare products development and quality assurance. Although the issues of data quality, transparency, and regulatory complexity are still present, the trend is evident: AI will further increase efficiency, accuracy, and safety throughout the product lifecycle. Healthcare organizations have the potential to fully leverage AI by adopting adaptive frameworks, integrated technologies, explainable frameworks, and patient-centered approaches [57]. Faster innovation, improved quality of products and more patient-oriented, responsive healthcare system is the future in which AI not only contributes to the development process but also initiates the process of creating safer, smarter and more effective healthcare solutions.

CONCLUSION

AI has become an avant-garde trend in the development of medical products and ensuring quality, which is changing the fundamental approach to the design, development, and continuity of medical devices, pharmaceuticals, diagnostics, and digital health-related solutions. Throughout the product lifecycle, and in the early stages of research and ideation, during the prototyping of products, manufacturing, and post-market surveillance, AI facilitates quicker innovation, greater accuracy, and a higher level of safety, as well as compliance with high regulatory standards. The combination of AI has been critical in handling the numerous problems that have been faced in the development of healthcare over the years such as time limits, scarcity of resources and unpredictable quality control which has led to a new paradigm where smart technologies can be used as a supplement to human knowledge.

The most important benefit of AI is its ability to handle large and intricate data sets and derive significant information that human beings cannot or cannot easily identify on their own. The use of machine learning, deep learning, natural language processing, and computer vision is becoming more and more common to predict product performance, optimization in design, defects, and automation of quality assurance processes. These abilities enable more effective testing of the products, more reliability, and even early risk detection, which will minimize mistakes and maximize patient safety. Also, predictive analytics and simulation tools based on AI will assist in making data-driven decisions during the development process that will enhance operational efficiency and the final product.

Although it has these benefits, there are also challenges associated with the introduction of AI in healthcare development. Such problems as access to data, quality and bias; the absence of transparency in complex models; regulatory uncertainty and ethical considerations related to patient privacy and algorithmic fairness should be controlled. To overcome these obstacles, data governance, explainable and interpretable AI models, and compliance with new regulatory guidelines are needed so that the AI-driven innovations would be safe and fair. In addition, it is also necessary to have a

ISSN : 3079-692X
Volume 1, Number 2, 2025
https://doi.org/10.70445/gjmlc.1.2.2025.93-111

cross-functional team consisting of clinicians, data scientists, engineers, and regulatory experts to integrate AI into the current processes and fulfill its potentials effectively.

In the future, AI in healthcare product development is characterized by adaptive, constantly learning models, incorporation with digital twins, robotics, and IoT-based ecosystems, and a closer correspondence with personalized medicine methods. The use of explainable AI and post-market surveillance will increase trust, compliance with regulations and AI-enabled automation will keep manufacturing and quality assurance simple. Collectively, these innovations have the potential to make the future of healthcare where AI does not merely hasten the progress but also promotes the development of higher-quality and patient-centered services that are dynamically responsive to changing clinical demands.

To sum it up, AI is a strong facilitator and a revolutionary engine of product development and quality assurance in healthcare. Its ability to boost innovation, safety, and process optimization cannot be compared to anything, as long as ethical, technical, and regulatory issues are carefully considered. With the ever-evolving and continuously growing AI technologies becoming employed in the healthcare industry as a seamless stream of processes, they will become central to the future of medical products, patient outcomes, and the ability to create a more efficient, safe, and responsive healthcare system. Responsible adoption of AI can enable developers and healthcare organizations to open new possibilities to provide safer, smarter, and more efficient solutions to address more intricate needs of modern medicine.

REFERENCES

[1]. Wang L, Liu Z, Liu A, Tao F. Artificial intelligence in product lifecycle management. The International Journal of Advanced Manufacturing Technology. 2021 May;114(3):771-96.

[2]. Terzi S, Bouras A, Dutta D, Garetti M, Kiritsis D (2010) Product lifecycle management-from its history to its new role. Int J Prod Lifecycle Manag 4(4):360–389

[3]. Hines P, Francis M, Found P (2006) Towards lean product lifecycle management. J Manuf Technol Manag 17:866–887

[4]. Sudarsan R, Fenves SJ, Sriram RD, Wang F (2005) A product information modeling framework for product lifecycle management. Comput Aided Des 37(13):1399–1411

[5]. Oluwagbade E, Vincent A, Oluwole O, Animasahun B. Lifecycle governance for explainable AI in pharmaceutical supply chains: a framework for continuous validation, bias auditing, and equitable healthcare delivery. Int J Eng Technol Res Manag. 2023 Nov;7(11):54.

ISSN : 3079-692X
Volume 1, Number 2, 2025
https://doi.org/10.70445/gjmlc.1.2.2025.93-111

[6]. Kommireddy VV. AI-Driven Process Automation in Product Lifecycle Management: A Transformative Approach. Journal of Computer Science and Technology Studies. 2025 Jul 1;7(7):91-100.

[7]. Wang T, Emami E, Jafarpour D, Tolentino R, Gore G, Rahimi SA. Integrating equity, diversity, and inclusion throughout the lifecycle of artificial intelligence for healthcare: a scoping review. PLOS Digital Health. 2025 Jul 14;4(7):e0000941.

[8]. Lyu G, Chu X, Xue D (2017) Product modeling from knowledge, distributed computing and lifecycle perspectives: A literature review. Comput Ind 84:1–13

[9]. Marongiu G, Bruno G, Chiabert P, Lombardi F. Evaluating the sustainability of Artificial Intelligence applications across the product lifecycle. InIFIP International Conference on Product Lifecycle Management 2024 Jul 9 (pp. 480-495). Cham: Springer Nature Switzerland.

[10]. Mittal P, Saini JS, Singh AK, Asthana S, Singh A. Product lifecycle management using AI-transforming the future of product innovation. Recent Trends in Intelligent Computing and Communication: Volume 2. 2025 Sep 30; 1:192.

[11]. Mohamad F. A Holistic Meta-Analysis of AI Implementation in the Pharmaceutical Product Lifecycle. InInternational Conference on Intelligent Computing and Communication 2024 Aug 30 (pp. 491-508). Singapore: Springer Nature Singapore.

[12]. Rojek I, Mikołajewski D, Dostatni E. Digital Twins in Product Lifecycle for Sustainability in Manufacturing and Maintenance. Applied Sciences. 2020; 11:31.

[13]. Abbate R, Caterino M, Fera M, Caputo F. Maintenance Digital Twin using vibration data. Procedia Computer Science. 2022; 200:546-55.

[14]. Rabah S, Assila A, Khouri E, Maier F, Ababsa F, bourny V, et al. Towards improving the future of manufacturing through digital twin and augmented reality technologies. Procedia Manufacturing. 2018; 17:460-7.

[15]. Qi Q, Tao F. Digital Twin and Big Data towards Smart Manufacturing and Industry 4.0: 360 Degree Comparison. IEEE Access. 2018; 6:3585-93.

[16]. Li J, Schaefer D, Milisavljevic-Syed J. A Decision-Based Framework for Predictive Maintenance Technique Selection in Industry 4.0. Procedia CIRP. 2022; 107:77-82.

[17]. Consilvio A, Sanetti P, Anguìta D, Crovetto C, Dambra C, Oneto L, et al., editors. Prescriptive Maintenance of Railway Infrastructure: From Data Analytics to Decision Support. 2019 6th International Conference on Models and Technologies for Intelligent Transportation Systems (MT-ITS); 2019 5-7 June 2019.

ISSN : 3079-692X
Volume 1, Number 2, 2025
https://doi.org/10.70445/gjmlc.1.2.2025.93-111

[18]. Luo W, Hu T, Zhu W, Tao F, editors. Digital twin modeling method for CNC machine tool. 2018 IEEE 15th International Conference on Networking, Sensing and Control (ICNSC); 2018 27-29 March 2018.

[19]. Schmidt C, Volz F, Stojanovic L, Sutschet G. Increasing Interoperability between Digital Twin Standards and Specifications: Transformation of DTDL to AAS. 2023;23(18):7742.

[20]. Kunzer BE, Berges ME, Dubrawski AJA. The Digital Twin Landscape at the Crossroads of Predictive Maintenance, Machine Learning and Physics Based Modeling. 2022; abs/2206.10462.

[21]. Werner R, Takacs R, Geier D, Becker T, Weissenberg N, Haße H, et al. The Challenge of Implementing Digital Twins in Operating Value Chains. 1772020.

[22]. Prabhu V, Oyekan J, Eng S, Woei LE, Tiwari A. Towards data-driven cyber attack damage and vulnerability estimation for manufacturing enterprises2018.

[23]. Chen Z, Huang L. Digital twins for information-sharing in remanufacturing supply chain: A review. Energy. 2020; 220:119712.

[24]. VanDerHorn E, Mahadevan S. Digital Twin: Generalization, characterization and implementation. Decis Support Syst. 2021; 145:113524.

[25]. Nor AK, Pedapati SR, Muhammad M, Leiva V. Overview of explainable artificial intelligence for prognostic and health management of industrial assets based on preferred reporting items for systematic reviews and meta-analyses. Sensors. 2021 Dec 1;21(23):8020.

[26]. Wärmefjord K, Söderberg R, Lindkvist L, Lindau B, Carlson J. Inspection Data to Support a Digital Twin for Geometry Assurance2017. V002T02A101 p.

[27]. Trauer J, Mutschler M, Mörtl M, Zimmermann M. Challenges in Implementing Digital Twins – a Survey2022.

[28]. Trauer J, Schweigert-Recksiek S, Schenk T, Baudisch T, Mörtl M, Zimmermann M. A Digital Twin Trust Framework for Industrial Application. Proceedings of the Design Society. 2022;2:293-302.

[29]. Khan TH, Noh C, Han S. Correspondence measure: a review for the digital twin standardization. The International Journal of Advanced Manufacturing Technology. 2023;128(5):1907-27.

[30]. Yli-Ojanperä M, Sierla S, Papakonstantinou N, Vyatkin V. Adapting an Agile Manufacturing Concept to the Reference Architecture Model Industry 4.0: a survey and case study. Journal of Industrial Information Integration. 2018; 15.

ISSN : 3079-692X
Volume 1, Number 2, 2025
https://doi.org/10.70445/gjmlc.1.2.2025.93-111

[31]. Kheir O, Smedts S, Jacoby A, Verwulgen S. Efficient Quality Management in MedTech Start-Ups (Based on ISO 13485). Medical devices (Auckland, NZ). 2021; 14:313-9.

[32]. Tao F, Sui F, Liu A, Qi Q, Zhang M, Song B, Guo Z, Lu SCY, Nee AYC (2019) Digital twin-driven product design framework. Int J Prod Res 57(12):3935–3953

[33]. Saha GC, Eni LN, Saha H, Parida PK, Rathinavelu R, Jain SK, Haldar B. Artificial intelligence in pharmaceutical Manufacturing: Enhancing quality control and decision making. Rivista Italiana di Filosofia Analitica Junior. 2023;14(2):2023.

[34]. Kreimeyer M (2012) A Product model to support PLM-based variant planning and management. In DS 70: Proceedings of DESIGN 2012, the 12th International Design Conference, Dubrovnik, Croatia (pp. 1741-1752).

[35]. Liu Y, Yang M, Guo Z. Reinforcement learning based optimal decision making towards product lifecycle sustainability. International Journal of Computer Integrated Manufacturing. 2022 Nov 2;35(10-11):1269-96.

[36]. Chen T, Jin Y, Qiu X, Chen X (2014) A hybrid fuzzy evaluation method for safety assessment of food-waste feed based on entropy and the analytic hierarchy process methods. Expert Syst Appl 41(16):7328–7337

[37]. Goswami MJ. Optimizing product lifecycle management with AI: From development to deployment. International Journal of Business Management and Visuals, ISSN. 2022:3006-2705.

[38]. Rostamzadeh R, Ghorabaee MK, Govindan K, Esmaeili A, Nobar HBK (2018) Evaluation of sustainable supply chain risk management using an integrated fuzzy TOPSIS-CRITIC approach. J Clean Prod 175:651–669

[39]. Tomasic I, Andersson A, Funk P (2017) Mixed-effect models for the analysis and optimization of sheet-metal assembly processes. IEEE Trans Ind Inform 99:1–1

[40]. Chen CC, Chuang MC (2008) Integrating the Kano model into a robust design approach to enhance customer satisfaction with product design. Int J Prod Econ 114(2):667–681

[41]. Li X, Peng Z, Du B, Guo J, Xu W, Zhuang K (2017) Hybrid artificial bee colony algorithm with a rescheduling strategy for solving flexible job shop scheduling problems. Comput Ind Eng 113:10–26

[42]. Wang L, Guo S, Li X, Du B, Xu W (2018) Distributed manufacturing resource selection strategy in cloud manufacturing. Int J Adv Manuf Technol 94(9-12):3375–3388

ISSN : 3079-692X
Volume 1, Number 2, 2025
https://doi.org/10.70445/gjmlc.1.2.2025.93-111

[43]. Javaid M, Haleem A, Singh RP, Suman R. Artificial intelligence applications for industry 4.0: A literature-based study. Journal of Industrial Integration and Management. 2022 Mar 21;7(01):83-111.

[44]. Tao F, Hu Y, Zhao D, Zhou Z, Zhang H, Lei Z (2009) Study on manufacturing grid resource service QoS modeling and evaluation. Int J Adv Manuf Technol 41(9-10):1034–1042

[45]. Dawson A. Robotic wireless sensor networks, big data-driven decision-making processes, and cyber-physical system-based real-time monitoring in sustainable product lifecycle management. Economics, Management, and Financial Markets. 2021;16(2):95-105.

[46]. Stark J (2020) PLM and the Internet of Things. In: Product Lifecycle Management, vol 1. Springer, Cham, pp 335–360

[47]. Sakao T, Nordholm AK. Requirements for a product lifecycle management system using Internet of Things and big data analytics for product-as-a-service. Frontiers in Sustainability. 2021 Aug 25;2:735550.

[48]. Li J, Tao F, Cheng Y, Zhao L (2015) Big data in product lifecycle management. Int J Adv Manuf Technol 81(1-4):667–684

[49]. Rahman H, D'Cruze RS, Ahmed MU, Sohlberg R, Sakao T, Funk P. Artificial intelligence-based life cycle engineering in industrial production: a systematic literature review. IEEE Access. 2022 Dec 19; 10:133001-15.

[50]. Tao F, Zhang H, Liu A, Nee AYC (2019) Digital twin in industry: state-of-the-art. IEEE Trans Ind Inform 15(4):2405–2415

[51]. Sanae A, Aicha SS, Adiba EB, Noredine EK. Towards vaccine lifecycle management (VLM): A systematic literature review of the issues and challenges. International Journal of Production Research. 2024 Nov 1;62(21):7998-8021.

[52]. Zhang Y, Zhang P, Tao F, Liu Y, Zuo Y (2019) Consensus aware manufacturing service collaboration optimization under blockchain based industrial internet platform. Comput Ind Eng 135(SEP):1025–1035

[53]. Tao F, Zhang L, Liu Y, Cheng Y, Wang L, Xu X (2015) Manufacturing service management in cloud manufacturing: overview and future research directions. J Manuf Sci Eng 137(4):040912

[54]. Liu H, Li Z, Song Z. Comprehensive lifecycle quality control of medical data-automated monitoring and feedback mechanisms based on artificial intelligence. Technology and Health Care. 2025 Apr 16:09287329251330222.

ISSN : 3079-692X
Volume 1, Number 2, 2025
https://doi.org/10.70445/gjmlc.1.2.2025.93-111

[55]. Rojek I, Dostatni E, Kopowski J, Macko M, Mikołajewski D. AI-based support system for monitoring the quality of a product within industry 4.0 paradigm. Sensors. 2022 Oct 22;22(21):8107.

[56]. Javaid M, Haleem A, Singh RP, Suman R. Artificial intelligence applications for industry 4.0: A literature-based study. Journal of Industrial Integration and Management. 2022 Mar 21;7(01):83-111.

[57]. Jastroch N. Trusted artificial intelligence: on the use of private data. InIFIP International Conference on Product Lifecycle Management 2020 Jul 5 (pp. 659-670). Cham: Springer International Publishing.